Nanologica collaborates with partners from early stage research towards final development projects in different capacities according to the type and extent of interaction. Nanologica conducts standard fee-for-service assignments, co-development projects and long-term partnerships.

Nanologica is a Swedish life science company dedicated to providing benefits to patients, through unique know-how in materials technology and a genuine interest in solving real problems in life science. Nanologica develops and manufactures nanoporous silica particles (NLAB SilicaTM) that have attractive properties for use in a variety of applications. Development work is carried out in close dialog with customers and partner organizations.

Fee for Service

Nanologica conducts fee-for-service feasibility studies for pharmaceutical companies with poorly soluble APIs in their pipeline. Successful formulations are then developed in partnership with the pharmaceutical company under a commercial agreement.

Commercial Development Projects

Nanologica has a strong track record in conducting commercial development projects in partnership with large and medium size pharmaceutical companies on development of formulations for oral drug delivery.
Typical projects concern enhancement of poorly soluble drugs as well as reformulation of approved drugs for new indications.

For more details, contact Adam Feiler, Head of Drug Delivery.

Technology Provider

Nanologica’s core-competence lies in manufacturing and application of NLAB SilicaTM. Our technology relies on the unique properties of this silica to provide benefits in pharmaceutical formulations.

Under technology transfer agreements, we work with CMOs and other technology providers to make the technology accessible to the broader pharmaceutical industry.

Academic Collaborations

Nanologica has ongoing research projects with academic groups and consortia, developing fundamental knowledge on various applications of NLAB SilicaTM. Our work is published in peer-reviewed scientific journals.
We support early stage research in a broad range of pharmaceutical formulations.